Suspected SK hynix HBM tech leaker arrested boarding flight to China
When you buy through links on our articles, Future and its syndication partners may earn a commission.
A man suspected of attempting to smuggle SK hynix tech secrets to China was apprehended at South Korea's Incheon International Airport earlier this month. DigiTimes reports that the former employee subcontractor aimed to leak the firm's proprietary high-bandwidth memory (HBM) packaging technology to entities based in China.
According to the source report, authorities had been aware of the activities of suspect 'Mr Kim' for several months. The Seoul Metropolitan Police Agency's Industrial Technology Security Investigation Unit made the dramatic airport arrest, moments before flight boarding, and charged Kim with violating South Korea's trade secret and unfair competition laws. Its investigators say that Kim stole critical data about HBM at around the same time he resigned as a subcontractor at SK hynix, at the beginning of the year.
Korean prosecutors allege that Kim kept printed and photographed records from his time at SK hynix. He went as far as removing SK hynix branding and 'confidential' markings from any material he captured, it is claimed. In total, reports say Kim was caught with a haul of 11,000 images from his time at SK hynix. Boldly, Kim is even said to have cited some of these stolen documents in job applications to Chinese firms, including Huawei's HiSilicon.
Above, we mentioned that the stolen proprietary data was mostly about HBM technology. More precisely, the almost-leaked SK hynix secrets were focused on the backend packaging stage of HBM, and hybrid bonding techniques, says reports.
HBM is widely used in AI accelerators, so it is understandable that Chinese rivals would covet SK hynix's work on fine-tuning the production of this kind of computer memory.
The case of Mr Kim is possibly only the tip of the iceberg, and there have been several other high-profile tech leaks to China involving rival companies like Samsung, for example.
South Korea already has reasonably strong deterrents to stem semiconductor IP theft. Individuals can face fines up to the equivalent of US$71,000 and up to 10 years behind bars. Harsher penalties and sentences can be imposed where strategic sectors fall victim to IP theft. Nevertheless, Korean authorities are making efforts to bolster legal deterrents, say reports.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
23 minutes ago
- Bloomberg
Swiss Growth Revised Up on US Export Surge Before Trump Tariffs
Switzerland's growth spurt into 2025 was even more pronounced than initially estimated, with the economy expanding at the fastest pace in two years. Before an anticipated hit from US tariffs, gross domestic product adjusted for large sport events increased 0.8% in the first quarter, the government said Monday. That's up from the 0.7% reported in a preliminary reading and more than the revised 0.6% recorded between October and December.


Bloomberg
an hour ago
- Bloomberg
Tom Cruise's Final ‘Mission Impossible' Tops China Box Office
Mission: Impossible – The Final Reckoning posted the biggest opening for a US film in the country this year, defying trade and geopolitical tensions between Washington and Beijing. Paramount Global 's eighth installment in the action franchise earned $25.2 million across 11,847 locations in China during the opening weekend, the studio said in a statement. The film is likely to become the top-performing US release in the country for 2025, with Warner Bros Entertainment Inc. 's A Minecraft Movie so far holding the lead with about $29 million since its April 4 debut, according to ticketing platform Maoyan.


Business Insider
an hour ago
- Business Insider
Nxera Pharma achieves development milestone in collaboration with Eli Lilly
Nxera Pharma announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly (LLY) and Company targeting diabetes and metabolic diseases, resulting in a payment to Nxera. The payment amount is undisclosed under the agreement with Lilly. However, Nxera makes this announcement in accordance with the timely disclosure requirements as the achievement of the milestone represents significant progress in research and development for Nxera. Nxera expects to receive the milestone payment in the third quarter of the fiscal year ending December 2025. Under the terms of the agreement, Nxera is eligible to receive development and commercial milestones totalling up to US$694 million, plus tiered royalties on global sales. Confident Investing Starts Here: